Corcept Therapeutics Incorporated

Corcept Therapeutics Beats on EPS, Stock Down 1.1%

Corcept Therapeutics reported a positive earnings surprise on EPS, which may indicate better-than-expected profitability. However, the stock reacted negatively, declining by 1.1%, suggesting that investors may have had concerns about other aspects of the company's performance or future outlook, particularly since revenue details were not disclosed.